Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

14  Enrolling
24  Total Trials
Pinned
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
Enrolling
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Enrolling
Conditions: Obesity, Overweight
Drugs: LY3841136
Age
18 - 75 years
Phase
II
Pinned
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
Enrolling
Conditions: Obesity, Overweight and Cardiovascular Disease
Trial Name
TRIUMPH-3
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
Enrolling
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)
Enrolling
Conditions: Obesity, Overweight and Osteoarthritis of the Knee
Trial Name
TRIUMPH-4
Drugs: Retatrutide
Age
≥18 years
Phase
III
Pinned
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Enrolling
Conditions: Obesity
Drugs: Mazdutide
Age
18 - 75 years
Phase
II
Pinned
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight a...
Enrolling
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18 years
Phase
III
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Enrolling
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18 - 75 years
Phase
II
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Enrolling
Conditions: Obesity
Drugs: retatrutide
Age
18 - 60 years
Phase
I
A Study of LY3841136 in Overweight and Obese Participants
Enrolling
Conditions: Overweight, Obesity
Drugs: LY3841136, Tirzepatide
Age
18 - 65 years
Phase
I
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Enrolling
Conditions: Obesity
Drugs: LY3841136
Age
18 - 65 years
Phase
I
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREA...
Enrolling
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18 years
Phase
II
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Enrolling
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Typ...
Enrolling
Conditions: Obesity, Overweight, Chronic kidney disease
Drugs: retatrutide
Age
≥18 years
Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
2  Not Yet Enrolling
24  Total Trials
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
Not Yet Enrolling
Conditions: Obesity
Trial Name
TRIUMPH-OUTCOMES
Drugs: retatrutide
Age
≥45 years
Phase
III
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Not Yet Enrolling
Conditions: Obesity
Drugs: Tirzepatide (LY3298176), Mibavademab
Age
≥18 years
Phase
II
8 
Completed Enrollment
24  Total Trials
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
Completed Enrollment
Conditions: Obesity, Overweight, Type 2 Diabetes
Trial Name
ATTAIN-2
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
Completed Enrollment
Conditions: Obesity
Trial Name
ATTAIN-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)
Completed Enrollment
Conditions: Obesity
Trial Name
ATTAIN-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
Completed Enrollment
Conditions: Obesity
Trial Name
SURMOUNT-MMO
Drugs: Tirzepatide
Age
≥40 years
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)
Completed Enrollment
Conditions: Obesity
Trial Name
SURMOUNT-1
Drugs: Tirzepatide, Placebo
Age
≥18 years
Phase
III
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Rel...
Completed Enrollment
Conditions: Obesity, Overweight
Drugs: Tirzepatide (LY3298176)
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Completed Enrollment
Conditions: Obesity, Heart Failure
Trial Name
SUMMIT
Drugs: Tirzepatide
Age
≥40 years
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)
Completed Enrollment
Conditions: Overweight, Obesity
Trial Name
SURMOUNT-5
Drugs: Tirzepatide, Semaglutide
Age
≥18 years
Phase
III